// App-Quantinova.ai

THU0603 (2018) : Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: moving towards targeted individualised treatment strategy

Researchers

Presenter

  • S.I. Nasef

Principal Investigators

  • G. El Deriny

  • M. Eissa

  • M.A. Mortada

  • W. Hassan

  • D. Mekkawy

  • Y. El Miedany

Medical Centers

  • Rheumatology and Rehabilitation, School of Medicine Suez Canal University, Ismaillia

  • Pediatrics, School of Medicine Alexandria University, Alexandria

  • Rheumatology and Rehabilitation, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

  • Rheumatology & Rehabilitation, Faculty of Medicine Zagazig University, Zagazig, Egypt

  • Rheumatology and Rehabilitation, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

  • Rheumatology and Rehabilitation, Faculty of Medicine, Ain-Shams University, Cairo, Egypt

  • Rheumatology, Darent Valley Hospital, Dartford, United Kingdom

Locations

  • United States

  • Egypt

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Ophthalmology (OP)

Disease

  • Rheumatoid arthritis

  • Uveitis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • leflunomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved